Episode Details
Back to Episodes
MindMed Soars Off Data and Its Impact on Psychedelics
Description
On today's episode of TDR's Trade To Black podcast, we're joined by Payton Nyquvest, Founder and CEO of Numinus Wellness (OTCMKTS: NUMIF), to explore MindMed's groundbreaking announcement from their Phase 2B trial. Take a look into the implications of MindMed's compelling data for anxiety treatments and the broader industry, highlighting the transformative potential of psychedelics in mental health innovation. #NuminusWellness #PsychedelicTherapy #mindmed Have you subscribed to the Baked In Newsletter? 📜 Join 20k+ unfiltered investing elites. Get Baked In delivered to your inbox for free, 5 days a week https://newsletter.thedalesreport.com... Add us on: Facebook: / thedalesreport Twitter: / thedalesreport Instagram: / dalesreport Website: https://thedalesreport.com/ The information provided in this video is for educational purposes only and should not be considered as financial or investment advice. Viewers are encouraged to conduct their own research and consult with a certified financial advisor before making any investment decisions.